Reports on the formation of the company PowderMed as a result of the buy-back of proprietary needle-free powder injection technology of Powderject Pharmaceuticals led by Clive Dix, the company's former head of research and development. Value of the sale; Initial focus to develop DNA vaccines; Effort of PowderMed to address the needs of the therapeutic vaccine market.